Friday, Jul 24, 2026 The claims desk. Receipts included. POWERED BY LENZ ↗
IsThis

HEALTH

The Claim

Ex vivo CRISPR-based therapies for sickle cell disease typically require myeloablative conditioning with busulfan before reinfusion of edited hematopoietic stem cells.

Verified by Lenz ·

The Short Version

Current evidence shows busulfan-based myeloablation is the standard preparative step before reinfusion in ex vivo CRISPR sickle cell therapies. FDA labeling for Casgevy and published trial reports describe busulfan conditioning, and broader reviews say busulfan remains the usual regimen across these autologous ex vivo approaches. Alternative conditioning strategies exist in research, but they are not yet typical practice.

Caveats

  • This is a statement about usual current practice, not a universal rule; alternative or less-toxic conditioning strategies are being studied.
  • The strongest direct evidence comes from Casgevy and closely related ex vivo gene-editing protocols, not from a large number of widely used CRISPR products.
  • Busulfan conditioning is clinically significant and toxic; the claim describes protocol requirements, not safety or superiority.

The Receipts

  1. Exagamglogene Autotemcel for Severe Sickle Cell Disease

    PubMed

  2. Highlights of Prescribing Information: CASGEVY (exagamglogene autotemcel)

    Vertex Pharmaceuticals

  3. Package Insert - LYFGENIA (lovotibeglogene autotemcel)

    U.S. Food and Drug Administration

  4. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

    The New England Journal of Medicine

  5. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    U.S. Food and Drug Administration

  6. Hematopoietic stem cell therapy with gene modification to treat sickle cell disease

    Stem Cell and Translational Medicine

  7. The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT

    ISCT Cytotherapy

  8. Lyfgenia Dosage Guide

    Drugs.com

  9. Hematopoietic stem cell therapy with gene modification to treat sickle cell disease

    PMC (Frontiers in Hematology)

  10. Casgevy (exagamglogene autotemcel) for sickle cell disease

    Sickle Cell Anemia News

+ 21 more sources — see the full list on Lenz

Filed Under

BusulfanCRISPRHematopoietic Stem CellsSickle Cell Disease

More Fact Checks